12.21.12
Probi, Stockholm, Sweden, has signed a business development agreement with Viva 5, Fort Lauderdale, FL, granting them license rights within Consumer Healthcare for Probi Digestis and Probi Defendum in North America. Probi will work with Viva 5 to further strengthen its commercial position as well as the presence and consumer awareness of the Probi brand in the North American market place. Viva 5 and Probi are already engaged in commercial discussions with select U.S.-based companies.
“The agreement between Probi and Viva 5 will be a significant opportunity to exploit the full potential for Probi Digestis and Probi Defendum in the U.S. marketplace. Targeted commercial agreements with a range of companies, each with a strong position in their respective sales channel, is required in order to achieve this. This is where the expertise and commercial network of Viva 5 will play an important role in complementing Probi’s existing partner network. The financial structure of the agreement is transparent and will allow both companies to capture attractive returns,” said Michael Oredsson, CEO of Probi.
“The agreement between Probi and Viva 5 will be a significant opportunity to exploit the full potential for Probi Digestis and Probi Defendum in the U.S. marketplace. Targeted commercial agreements with a range of companies, each with a strong position in their respective sales channel, is required in order to achieve this. This is where the expertise and commercial network of Viva 5 will play an important role in complementing Probi’s existing partner network. The financial structure of the agreement is transparent and will allow both companies to capture attractive returns,” said Michael Oredsson, CEO of Probi.
